Cargando…

Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men

OBJECTIVE: HPV causes ~90% of anal cancer and HPV16 is the type most commonly associated with anal cancer. Gay and bisexual men (GBM) are at greatly increased risk. We investigated patterns of vaccine-preventable anal HPV in older GBM. METHODS: The Study of the Prevention of Anal Cancer (SPANC) is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Poynten, I. Mary, Tabrizi, Sepehr N., Jin, Fengyi, Templeton, David J., Machalek, Dorothy A., Cornall, Alyssa, Phillips, Samuel, Fairley, Christopher K., Garland, Suzanne M., Law, Carmella, Carr, Andrew, Hillman, Richard J., Grulich, Andrew E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883229/
https://www.ncbi.nlm.nih.gov/pubmed/28720461
http://dx.doi.org/10.1016/j.pvr.2017.02.003
_version_ 1783311605903130624
author Poynten, I. Mary
Tabrizi, Sepehr N.
Jin, Fengyi
Templeton, David J.
Machalek, Dorothy A.
Cornall, Alyssa
Phillips, Samuel
Fairley, Christopher K.
Garland, Suzanne M.
Law, Carmella
Carr, Andrew
Hillman, Richard J.
Grulich, Andrew E.
author_facet Poynten, I. Mary
Tabrizi, Sepehr N.
Jin, Fengyi
Templeton, David J.
Machalek, Dorothy A.
Cornall, Alyssa
Phillips, Samuel
Fairley, Christopher K.
Garland, Suzanne M.
Law, Carmella
Carr, Andrew
Hillman, Richard J.
Grulich, Andrew E.
author_sort Poynten, I. Mary
collection PubMed
description OBJECTIVE: HPV causes ~90% of anal cancer and HPV16 is the type most commonly associated with anal cancer. Gay and bisexual men (GBM) are at greatly increased risk. We investigated patterns of vaccine-preventable anal HPV in older GBM. METHODS: The Study of the Prevention of Anal Cancer (SPANC) is an ongoing, prospective cohort study of HIV-positive and HIV-negative Australian GBM. Participants completed questionnaires and underwent an anal swab for HPV genotyping using Roche Linear Array. We analysed baseline data from SPANC by HPV type, mean number of types, stratified by age and HIV status. RESULTS: Anal HPV results from 606 (98.2%) of 617 participants (median age 49 years, 35.7% HIV-positive) showed 525 (86.7%) had ≥1 HPV type and 178 (29.4%) had HPV16. Over one third of participants (214, 35.3%) had no nonavalent vaccine-preventable types detected. Two (0.3%) participants had all quadrivalent types and none had all nonavalent vaccine types. HIV-positive participants (p<0.001) and younger participants (p=0.059) were more likely to have more vaccine-preventable HPV types detected. CONCLUSION: Anal HPV was highly prevalent in this largely community-based GBM cohort. Vaccine-preventable HPV16 was detected in approximately one third of participants. These findings suggest that the potential efficacy of HPV vaccination of older GBM should be explored.
format Online
Article
Text
id pubmed-5883229
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-58832292018-04-11 Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men Poynten, I. Mary Tabrizi, Sepehr N. Jin, Fengyi Templeton, David J. Machalek, Dorothy A. Cornall, Alyssa Phillips, Samuel Fairley, Christopher K. Garland, Suzanne M. Law, Carmella Carr, Andrew Hillman, Richard J. Grulich, Andrew E. Papillomavirus Res Article OBJECTIVE: HPV causes ~90% of anal cancer and HPV16 is the type most commonly associated with anal cancer. Gay and bisexual men (GBM) are at greatly increased risk. We investigated patterns of vaccine-preventable anal HPV in older GBM. METHODS: The Study of the Prevention of Anal Cancer (SPANC) is an ongoing, prospective cohort study of HIV-positive and HIV-negative Australian GBM. Participants completed questionnaires and underwent an anal swab for HPV genotyping using Roche Linear Array. We analysed baseline data from SPANC by HPV type, mean number of types, stratified by age and HIV status. RESULTS: Anal HPV results from 606 (98.2%) of 617 participants (median age 49 years, 35.7% HIV-positive) showed 525 (86.7%) had ≥1 HPV type and 178 (29.4%) had HPV16. Over one third of participants (214, 35.3%) had no nonavalent vaccine-preventable types detected. Two (0.3%) participants had all quadrivalent types and none had all nonavalent vaccine types. HIV-positive participants (p<0.001) and younger participants (p=0.059) were more likely to have more vaccine-preventable HPV types detected. CONCLUSION: Anal HPV was highly prevalent in this largely community-based GBM cohort. Vaccine-preventable HPV16 was detected in approximately one third of participants. These findings suggest that the potential efficacy of HPV vaccination of older GBM should be explored. Elsevier 2017-02-21 /pmc/articles/PMC5883229/ /pubmed/28720461 http://dx.doi.org/10.1016/j.pvr.2017.02.003 Text en Crown Copyright © 2017 Published by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Poynten, I. Mary
Tabrizi, Sepehr N.
Jin, Fengyi
Templeton, David J.
Machalek, Dorothy A.
Cornall, Alyssa
Phillips, Samuel
Fairley, Christopher K.
Garland, Suzanne M.
Law, Carmella
Carr, Andrew
Hillman, Richard J.
Grulich, Andrew E.
Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men
title Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men
title_full Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men
title_fullStr Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men
title_full_unstemmed Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men
title_short Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men
title_sort vaccine-preventable anal human papillomavirus in australian gay and bisexual men
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883229/
https://www.ncbi.nlm.nih.gov/pubmed/28720461
http://dx.doi.org/10.1016/j.pvr.2017.02.003
work_keys_str_mv AT poyntenimary vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen
AT tabrizisepehrn vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen
AT jinfengyi vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen
AT templetondavidj vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen
AT machalekdorothya vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen
AT cornallalyssa vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen
AT phillipssamuel vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen
AT fairleychristopherk vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen
AT garlandsuzannem vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen
AT lawcarmella vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen
AT carrandrew vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen
AT hillmanrichardj vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen
AT grulichandrewe vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen
AT vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen